BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 32087612)

  • 1. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.
    Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V
    Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis.
    Whittle S; Venkatramani R; Schönstein A; Pack SD; Alaggio R; Vokuhl C; Rudzinski ER; Wulf AL; Zin A; Gruver JR; Arnold MA; Merks JHM; Hettmer S; Koscielniak E; Barr FG; Hawkins DS; Bisogno G; Sparber-Sauer M
    Eur J Cancer; 2022 Jun; 168():56-64. PubMed ID: 35452896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
    Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
    Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
    Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.
    Alaggio R; Zhang L; Sung YS; Huang SC; Chen CL; Bisogno G; Zin A; Agaram NP; LaQuaglia MP; Wexler LH; Antonescu CR
    Am J Surg Pathol; 2016 Feb; 40(2):224-35. PubMed ID: 26501226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis.
    Walther C; Mayrhofer M; Nilsson J; Hofvander J; Jonson T; Mandahl N; Øra I; Gisselsson D; Mertens F
    Genes Chromosomes Cancer; 2016 Jan; 55(1):3-15. PubMed ID: 26482321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma.
    de Traux De Wardin H; Cyrta J; Dermawan JK; Guillemot D; Orbach D; Aerts I; Pierron G; Antonescu CR
    Genes Chromosomes Cancer; 2024 Apr; 63(4):e23232. PubMed ID: 38607246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histology and fusion status in rhabdomyosarcoma.
    Rudzinski ER
    Am Soc Clin Oncol Educ Book; 2013; ():425-8. PubMed ID: 23714565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma.
    Karanian M; Pissaloux D; Gomez-Brouchet A; Chevenet C; Le Loarer F; Fernandez C; Minard V; Corradini N; Castex MP; Duc-Gallet A; Blay JY; Tirode F
    Am J Surg Pathol; 2020 May; 44(5):607-616. PubMed ID: 32187044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation profiling reveals novel molecular classes of rhabdomyosarcoma.
    Clay MR; Patel A; Tran Q; Hedges DJ; Chang TC; Stewart E; Charville G; Cline C; Dyer MA; Orr BA
    Sci Rep; 2021 Nov; 11(1):22213. PubMed ID: 34782706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
    [No Abstract]   [Full Text] [Related]  

  • 13. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYOD1 as a prognostic indicator in rhabdomyosarcoma.
    Ahmed AA; Habeebu S; Farooqi MS; Gamis AS; Gonzalez E; Flatt T; Sherman A; Surrey L; Arnold MA; Conces M; Koo S; Dioufa N; Barr FG; Tsokos MG
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29085. PubMed ID: 33913590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.
    Allen-Rhoades W; Lupo PJ; Scheurer ME; Chi YY; Kuttesch JF; Venkatramani R; Meyer WH; Mascarenhas L
    Cancer Med; 2023 May; 12(9):10222-10229. PubMed ID: 37016270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
    Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
    Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
    Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
    Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm.
    Giannikopoulos P; Parham DM
    Pediatr Dev Pathol; 2021; 24(5):395-404. PubMed ID: 34107813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
    Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
    Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.